Update: Added data from study of new patient populations Medtronic (NYSE:MDT) said today it released the 1st real-world registry study of its CoreValve transcatheter aortic valve implant, reporting outcomes in-line with its clinical trials of the device. The medtech giant also released new data from 3 studies focusing on new patient populations with significant comorbidities today. […]
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
TCT 2015: More 2-year data on Bard’s Lutonix DEB
C.R. Bard (NYSE:BCR) yesterday released 2-year results from a small group of patients in a real-world registry study of its Lutonix drug-eluting balloon at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. Bard said the Lutonix 035 device, which is designed to treat peripheral artery disease, showed a 94.3% rate of freedom from target lesion revascularization in […]
TCT 2015: First-in-human results for Biotronik’s Dreams 2G absorbable stent
UPDATED Oct. 13, 2015 with expanded comments from Biotronik. Early data on a fully bioabsorbable metal stent, the Dreams 2G made by Biotronik, showed that the device performed better and was just as safe as older iterations of the technology, researchers said today at the annual Transcatheter Cardiovascular Therapies conference in San Francisco. The Dreams 2G […]
TCT 2015: Abbott’s Absorb meets endpoint in U.S. pivotal trial
The Absorb bioabsorbable stent made by Abbott (NYSE:ABT) met its primary endpoint in a U.S. clinical trial that will be used to back a bid for FDA approval, researchers said today at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco. One-year data from the Absorb III trial of 2,008 patients showed that the Absorb […]
TCT 2015: Early data on Medtronic’s drug-filled stent
Early data from a small set of patients implanted with Medtronic‘s (NYSE:MDT) drug-filled stent, presented today at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed that the device “achieved rapid and well-controlled stent coverage,” the company said today. The DFS is built using the Fridley, Minn.-based medical device giant’s Resolute Integrity and Resolute Onyx stents, using […]
FDA clears Endologix’ AFX2 bifurcated stent graft
Endologix (NSDQ:ELGX) said it won FDA premarket approval for its AFX2 bifurcated endograft system for treating abdominal aortic aneurysms. The system is the newest-generation of AFX endovascular AAA product from the Irvine, Calif.-based company. The new version of the device reduces delivery and deployment procedure steps and can facilitate percutaneous endovascular aneurysm repair through a low-profile […]
Procyrion drums up $10m Series B for Aortix heart pump
Procyrion said it raised a $10 million Series B round for its Aortix heart pump, led by the consortium of Fannin Partners, Scientific Health Development and an unnamed strategic investor. Prior backers and new investors also participated, Houston-based Procyrion said. The Aortix pump is designed to use a principle called fluid entrainment to help unburden the heart muscle. Unlike […]
UPDATE: St. Jude Medical closes $3B Thoratec buy
St. Jude Medical (NYSE:STJ) yesterday closed its $3.3 billion buyout of Thoratec, a day after the implantable heart pump maker’s shareholders approved the $63.50-per-share deal. “St. Jude Medical is excited to bring together 2 companies that are considered heart failure therapy leaders and build on our established franchise that is now uniquely positioned to offer physicians and patients innovative solutions across […]
FDA clears Medtronic’s Tyrx envelope for DBS devices
Medtronic (NYSE:MDT) said today that it’s launching its Tyrx surgical envelope in the U.S. for use with deep-brain stimulation devices, after it won 510(k) clearance from the FDA for use of the infection-fighting envelope with implantable neurostimulators. Fridley, Minn.-based Medtronic said it’s planning to make the Tyrx device, acquired for $160 million in January 2014, available for […]
Wyeth, Cordis bury the hatchet in stent patent spat with Abbott, Boston Scientific
A quartet of medical companies agreed yesterday to bury the hatchet in their 6-year-old battle over the patent covering drug-eluting stent technology. Wyeth, now part of Pfizer (NYSE:PFE), and onetime Johnson & Johnson (NYSE:JNJ) subsidiary Cordis (which this week became a part of Cardinal Health), sued Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) in 2009, alleging that […]
Cardiovascular Systems plunges on Q1 prelims
Cardiovascular Systems (NSDQ:CSII) shares plunged 19% today after the medical device company missed expectations with its preliminary fiscal 1st quarter numbers. St. Paul, Minn.-based Cardiovascular Systems said it expects to post net losses of -$13.1 million to -$13.9 million, or -41¢ to -43¢ per share, on sales of $43.9 million. Analysts were looking for losses per share of […]